Company Details

Opharmic Technology (HK) Limited

Currently worldwide, intravitreal injection is the most common treatment for a wide range of retinal diseases. It is a horrifying, painful process that could induce a series of side effects. For most patients, they have to endure monthly, or even weekly injections to effectively treat their disease. Developed by Sonikure Technology aiming to replace needle injections, the Sonikure device safely and efficiently deliver drugs into the eye via our patented low energy and low intensity ultrasonic technology. Compatible to commercial viable eye drugs, the treatment is non-invasive, painless, and proven complication-free in pre-clinical trials.

Unit 208C, 2/F, Enterprise Place No. 5 Science Park West Avenue Hong Kong Sicence Park, Pak Shek Kok,HK
+852 2520 0220
Ms. Sarah Cheung

The information provided on this page is for reference only. Please refer to the latest information published by the partner company.

Contact Us

For general enquiry, or questions about HKSTP’s services and support, please enter your email address and query here.